A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties &

Updated 06/21/2024

Status Not yet recruiting

Clinical Trial Summary

This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety, tolerability and preliminary efficacy of 9MW3811 in patients with advanced solid tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05911984
Study type	Interventional
Source	Mabwell (Shanghai) Bioscience Co., Ltd.
Contact
Status	Not yet recruiting
Phase	Phase 1
Start date	June 30, 2023
Completion date	March 2024

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04864379` - Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors	Phase 1
	Recruiting	`NCT04165590` - Plasmodium Immunotherapy for Advanced Malignant Solid Tumors	Phase 1/Phase 2
	Terminated	`NCT05098405` - First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors	Phase 1
	Recruiting	`NCT06150183` - Safety and Preliminary Efficacy of BNT314 With or Without an Immune Checkpoint Inhibitor in Cancer Patients With Malignant Solid Tumors	Phase 1/Phase 2
	Recruiting	`NCT05396339` - A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.	Phase 1/Phase 2
	Recruiting	`NCT03171220` - Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors	Phase 1/Phase 2
	Recruiting	`NCT04241835` - A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function	Phase 1
	Active, not recruiting	`NCT03662815` - Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor	Phase 1
	Not yet recruiting	`NCT06166472` - A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor	Phase 1
	Recruiting	`NCT05477849` - A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients With Solid Tumors	Phase 1
	Not yet recruiting	`NCT04275050` - A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets	Phase 1
	Recruiting	`NCT04758897` - Clinical Study of VG161 in Subjects With Advanced Malignant Solid Tumors	Phase 1